- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Biosimilar Insulin market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Biosimilar Insulin market size is estimated to be worth US$ 2632.1 million in 2021 and is forecast to a readjusted size of USD 6421.8 million by 2028 with a CAGR of 13.6% during review period. Hospital accounting for % of the Biosimilar Insulin global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Biosimilar Insulin Glargine segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Biosimilar Insulin include Eli Lilly, Sanofi, Gan&Lee, Tonghua Dongbao, and United Laboratory, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Biosimilar Insulin market is split by Type and by Distribution Channel. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Distribution Channel in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Biosimilar Insulin Glargine
Biosimilar Insulin Lispro
Other
Market segment by Distribution Channel can be divided into
Hospital
Retail Pharmacy
Others
The key market players for global Biosimilar Insulin market are listed below:
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Biosimilar Insulin product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Biosimilar Insulin, with price, sales, revenue and global market share of Biosimilar Insulin from 2019 to 2022.
Chapter 3, the Biosimilar Insulin competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Biosimilar Insulin breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, distribution channel, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Biosimilar Insulin market forecast, by regions, type and distribution channel, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biosimilar Insulin.
Chapter 13, 14, and 15, to describe Biosimilar Insulin sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Biosimilar Insulin Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Biosimilar Insulin Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Biosimilar Insulin Glargine
1.2.3 Biosimilar Insulin Lispro
1.2.4 Other
1.3 Market Analysis by Distribution Channel
1.3.1 Overview: Global Biosimilar Insulin Revenue by Distribution Channel: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Global Biosimilar Insulin Market Size & Forecast
1.4.1 Global Biosimilar Insulin Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Biosimilar Insulin Sales in Volume (2017-2028)
1.4.3 Global Biosimilar Insulin Price (2017-2028)
1.5 Global Biosimilar Insulin Production Capacity Analysis
1.5.1 Global Biosimilar Insulin Total Production Capacity (2017-2028)
1.5.2 Global Biosimilar Insulin Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Biosimilar Insulin Market Drivers
1.6.2 Biosimilar Insulin Market Restraints
1.6.3 Biosimilar Insulin Trends Analysis
2 Manufacturers Profiles
2.1 Eli Lilly
2.1.1 Eli Lilly Details
2.1.2 Eli Lilly Major Business
2.1.3 Eli Lilly Biosimilar Insulin Product and Services
2.1.4 Eli Lilly Biosimilar Insulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Biosimilar Insulin Product and Services
2.2.4 Sanofi Biosimilar Insulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Gan&Lee
2.3.1 Gan&Lee Details
2.3.2 Gan&Lee Major Business
2.3.3 Gan&Lee Biosimilar Insulin Product and Services
2.3.4 Gan&Lee Biosimilar Insulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Tonghua Dongbao
2.4.1 Tonghua Dongbao Details
2.4.2 Tonghua Dongbao Major Business
2.4.3 Tonghua Dongbao Biosimilar Insulin Product and Services
2.4.4 Tonghua Dongbao Biosimilar Insulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 United Laboratory
2.5.1 United Laboratory Details
2.5.2 United Laboratory Major Business
2.5.3 United Laboratory Biosimilar Insulin Product and Services
2.5.4 United Laboratory Biosimilar Insulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Geropharm
2.6.1 Geropharm Details
2.6.2 Geropharm Major Business
2.6.3 Geropharm Biosimilar Insulin Product and Services
2.6.4 Geropharm Biosimilar Insulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Biocon
2.7.1 Biocon Details
2.7.2 Biocon Major Business
2.7.3 Biocon Biosimilar Insulin Product and Services
2.7.4 Biocon Biosimilar Insulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Wockhardt
2.8.1 Wockhardt Details
2.8.2 Wockhardt Major Business
2.8.3 Wockhardt Biosimilar Insulin Product and Services
2.8.4 Wockhardt Biosimilar Insulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Biosimilar Insulin Breakdown Data by Manufacturer
3.1 Global Biosimilar Insulin Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Biosimilar Insulin Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Biosimilar Insulin
3.4 Market Concentration Rate
3.4.1 Top 3 Biosimilar Insulin Manufacturer Market Share in 2021
3.4.2 Top 6 Biosimilar Insulin Manufacturer Market Share in 2021
3.5 Global Biosimilar Insulin Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Biosimilar Insulin Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Biosimilar Insulin Market Size by Region
4.1.1 Global Biosimilar Insulin Sales in Volume by Region (2017-2028)
4.1.2 Global Biosimilar Insulin Revenue by Region (2017-2028)
4.2 North America Biosimilar Insulin Revenue (2017-2028)
4.3 Europe Biosimilar Insulin Revenue (2017-2028)
4.4 Asia-Pacific Biosimilar Insulin Revenue (2017-2028)
4.5 South America Biosimilar Insulin Revenue (2017-2028)
4.6 Middle East and Africa Biosimilar Insulin Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Biosimilar Insulin Sales in Volume by Type (2017-2028)
5.2 Global Biosimilar Insulin Revenue by Type (2017-2028)
5.3 Global Biosimilar Insulin Price by Type (2017-2028)
6 Market Segment by Distribution Channel
6.1 Global Biosimilar Insulin Sales in Volume by Distribution Channel (2017-2028)
6.2 Global Biosimilar Insulin Revenue by Distribution Channel (2017-2028)
6.3 Global Biosimilar Insulin Price by Distribution Channel (2017-2028)
7 North America by Country, by Type, and by Distribution Channel
7.1 North America Biosimilar Insulin Sales by Type (2017-2028)
7.2 North America Biosimilar Insulin Sales by Distribution Channel (2017-2028)
7.3 North America Biosimilar Insulin Market Size by Country
7.3.1 North America Biosimilar Insulin Sales in Volume by Country (2017-2028)
7.3.2 North America Biosimilar Insulin Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Distribution Channel
8.1 Europe Biosimilar Insulin Sales by Type (2017-2028)
8.2 Europe Biosimilar Insulin Sales by Distribution Channel (2017-2028)
8.3 Europe Biosimilar Insulin Market Size by Country
8.3.1 Europe Biosimilar Insulin Sales in Volume by Country (2017-2028)
8.3.2 Europe Biosimilar Insulin Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Distribution Channel
9.1 Asia-Pacific Biosimilar Insulin Sales by Type (2017-2028)
9.2 Asia-Pacific Biosimilar Insulin Sales by Distribution Channel (2017-2028)
9.3 Asia-Pacific Biosimilar Insulin Market Size by Region
9.3.1 Asia-Pacific Biosimilar Insulin Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Biosimilar Insulin Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Distribution Channel
10.1 South America Biosimilar Insulin Sales by Type (2017-2028)
10.2 South America Biosimilar Insulin Sales by Distribution Channel (2017-2028)
10.3 South America Biosimilar Insulin Market Size by Country
10.3.1 South America Biosimilar Insulin Sales in Volume by Country (2017-2028)
10.3.2 South America Biosimilar Insulin Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Distribution Channel
11.1 Middle East & Africa Biosimilar Insulin Sales by Type (2017-2028)
11.2 Middle East & Africa Biosimilar Insulin Sales by Distribution Channel (2017-2028)
11.3 Middle East & Africa Biosimilar Insulin Market Size by Country
11.3.1 Middle East & Africa Biosimilar Insulin Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Biosimilar Insulin Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Biosimilar Insulin and Key Manufacturers
12.2 Manufacturing Costs Percentage of Biosimilar Insulin
12.3 Biosimilar Insulin Production Process
12.4 Biosimilar Insulin Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Biosimilar Insulin Typical Distributors
13.3 Biosimilar Insulin Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global Biosimilar Insulin Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Biosimilar Insulin Revenue by Distribution Channel, (USD Million), 2017 & 2021 & 2028
Table 3. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 4. Eli Lilly Major Business
Table 5. Eli Lilly Biosimilar Insulin Product and Services
Table 6. Eli Lilly Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Sanofi Basic Information, Manufacturing Base and Competitors
Table 8. Sanofi Major Business
Table 9. Sanofi Biosimilar Insulin Product and Services
Table 10. Sanofi Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Gan&Lee Basic Information, Manufacturing Base and Competitors
Table 12. Gan&Lee Major Business
Table 13. Gan&Lee Biosimilar Insulin Product and Services
Table 14. Gan&Lee Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors
Table 16. Tonghua Dongbao Major Business
Table 17. Tonghua Dongbao Biosimilar Insulin Product and Services
Table 18. Tonghua Dongbao Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. United Laboratory Basic Information, Manufacturing Base and Competitors
Table 20. United Laboratory Major Business
Table 21. United Laboratory Biosimilar Insulin Product and Services
Table 22. United Laboratory Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Geropharm Basic Information, Manufacturing Base and Competitors
Table 24. Geropharm Major Business
Table 25. Geropharm Biosimilar Insulin Product and Services
Table 26. Geropharm Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Biocon Basic Information, Manufacturing Base and Competitors
Table 28. Biocon Major Business
Table 29. Biocon Biosimilar Insulin Product and Services
Table 30. Biocon Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Wockhardt Basic Information, Manufacturing Base and Competitors
Table 32. Wockhardt Major Business
Table 33. Wockhardt Biosimilar Insulin Product and Services
Table 34. Wockhardt Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Global Biosimilar Insulin Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Unit)
Table 36. Global Biosimilar Insulin Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 37. Market Position of Manufacturers in Biosimilar Insulin, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 38. Global Biosimilar Insulin Production Capacity by Company, (K Unit): 2020 VS 2021
Table 39. Head Office and Biosimilar Insulin Production Site of Key Manufacturer
Table 40. Biosimilar Insulin New Entrant and Capacity Expansion Plans
Table 41. Biosimilar Insulin Mergers & Acquisitions in the Past Five Years
Table 42. Global Biosimilar Insulin Sales by Region (2017-2022) & (K Unit)
Table 43. Global Biosimilar Insulin Sales by Region (2023-2028) & (K Unit)
Table 44. Global Biosimilar Insulin Revenue by Region (2017-2022) & (USD Million)
Table 45. Global Biosimilar Insulin Revenue by Region (2023-2028) & (USD Million)
Table 46. Global Biosimilar Insulin Sales by Type (2017-2022) & (K Unit)
Table 47. Global Biosimilar Insulin Sales by Type (2023-2028) & (K Unit)
Table 48. Global Biosimilar Insulin Revenue by Type (2017-2022) & (USD Million)
Table 49. Global Biosimilar Insulin Revenue by Type (2023-2028) & (USD Million)
Table 50. Global Biosimilar Insulin Price by Type (2017-2022) & (US$/Unit)
Table 51. Global Biosimilar Insulin Price by Type (2023-2028) & (US$/Unit)
Table 52. Global Biosimilar Insulin Sales by Distribution Channel (2017-2022) & (K Unit)
Table 53. Global Biosimilar Insulin Sales by Distribution Channel (2023-2028) & (K Unit)
Table 54. Global Biosimilar Insulin Revenue by Distribution Channel (2017-2022) & (USD Million)
Table 55. Global Biosimilar Insulin Revenue by Distribution Channel (2023-2028) & (USD Million)
Table 56. Global Biosimilar Insulin Price by Distribution Channel (2017-2022) & (US$/Unit)
Table 57. Global Biosimilar Insulin Price by Distribution Channel (2023-2028) & (US$/Unit)
Table 58. North America Biosimilar Insulin Sales by Country (2017-2022) & (K Unit)
Table 59. North America Biosimilar Insulin Sales by Country (2023-2028) & (K Unit)
Table 60. North America Biosimilar Insulin Revenue by Country (2017-2022) & (USD Million)
Table 61. North America Biosimilar Insulin Revenue by Country (2023-2028) & (USD Million)
Table 62. North America Biosimilar Insulin Sales by Type (2017-2022) & (K Unit)
Table 63. North America Biosimilar Insulin Sales by Type (2023-2028) & (K Unit)
Table 64. North America Biosimilar Insulin Sales by Distribution Channel (2017-2022) & (K Unit)
Table 65. North America Biosimilar Insulin Sales by Distribution Channel (2023-2028) & (K Unit)
Table 66. Europe Biosimilar Insulin Sales by Country (2017-2022) & (K Unit)
Table 67. Europe Biosimilar Insulin Sales by Country (2023-2028) & (K Unit)
Table 68. Europe Biosimilar Insulin Revenue by Country (2017-2022) & (USD Million)
Table 69. Europe Biosimilar Insulin Revenue by Country (2023-2028) & (USD Million)
Table 70. Europe Biosimilar Insulin Sales by Type (2017-2022) & (K Unit)
Table 71. Europe Biosimilar Insulin Sales by Type (2023-2028) & (K Unit)
Table 72. Europe Biosimilar Insulin Sales by Distribution Channel (2017-2022) & (K Unit)
Table 73. Europe Biosimilar Insulin Sales by Distribution Channel (2023-2028) & (K Unit)
Table 74. Asia-Pacific Biosimilar Insulin Sales by Region (2017-2022) & (K Unit)
Table 75. Asia-Pacific Biosimilar Insulin Sales by Region (2023-2028) & (K Unit)
Table 76. Asia-Pacific Biosimilar Insulin Revenue by Region (2017-2022) & (USD Million)
Table 77. Asia-Pacific Biosimilar Insulin Revenue by Region (2023-2028) & (USD Million)
Table 78. Asia-Pacific Biosimilar Insulin Sales by Type (2017-2022) & (K Unit)
Table 79. Asia-Pacific Biosimilar Insulin Sales by Type (2023-2028) & (K Unit)
Table 80. Asia-Pacific Biosimilar Insulin Sales by Distribution Channel (2017-2022) & (K Unit)
Table 81. Asia-Pacific Biosimilar Insulin Sales by Distribution Channel (2023-2028) & (K Unit)
Table 82. South America Biosimilar Insulin Sales by Country (2017-2022) & (K Unit)
Table 83. South America Biosimilar Insulin Sales by Country (2023-2028) & (K Unit)
Table 84. South America Biosimilar Insulin Revenue by Country (2017-2022) & (USD Million)
Table 85. South America Biosimilar Insulin Revenue by Country (2023-2028) & (USD Million)
Table 86. South America Biosimilar Insulin Sales by Type (2017-2022) & (K Unit)
Table 87. South America Biosimilar Insulin Sales by Type (2023-2028) & (K Unit)
Table 88. South America Biosimilar Insulin Sales by Distribution Channel (2017-2022) & (K Unit)
Table 89. South America Biosimilar Insulin Sales by Distribution Channel (2023-2028) & (K Unit)
Table 90. Middle East & Africa Biosimilar Insulin Sales by Region (2017-2022) & (K Unit)
Table 91. Middle East & Africa Biosimilar Insulin Sales by Region (2023-2028) & (K Unit)
Table 92. Middle East & Africa Biosimilar Insulin Revenue by Region (2017-2022) & (USD Million)
Table 93. Middle East & Africa Biosimilar Insulin Revenue by Region (2023-2028) & (USD Million)
Table 94. Middle East & Africa Biosimilar Insulin Sales by Type (2017-2022) & (K Unit)
Table 95. Middle East & Africa Biosimilar Insulin Sales by Type (2023-2028) & (K Unit)
Table 96. Middle East & Africa Biosimilar Insulin Sales by Distribution Channel (2017-2022) & (K Unit)
Table 97. Middle East & Africa Biosimilar Insulin Sales by Distribution Channel (2023-2028) & (K Unit)
Table 98. Biosimilar Insulin Raw Material
Table 99. Key Manufacturers of Biosimilar Insulin Raw Materials
Table 100. Direct Channel Pros & Cons
Table 101. Indirect Channel Pros & Cons
Table 102. Biosimilar Insulin Typical Distributors
Table 103. Biosimilar Insulin Typical Customers
List of Figures
Figure 1. Biosimilar Insulin Picture
Figure 2. Global Biosimilar Insulin Revenue Market Share by Type in 2021
Figure 3. Biosimilar Insulin Glargine
Figure 4. Biosimilar Insulin Lispro
Figure 5. Other
Figure 6. Global Biosimilar Insulin Revenue Market Share by Distribution Channel in 2021
Figure 7. Hospital
Figure 8. Retail Pharmacy
Figure 9. Others
Figure 10. Global Biosimilar Insulin Revenue, (USD Million) & (K Unit): 2017 & 2021 & 2028
Figure 11. Global Biosimilar Insulin Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Biosimilar Insulin Sales (2017-2028) & (K Unit)
Figure 13. Global Biosimilar Insulin Price (2017-2028) & (US$/Unit)
Figure 14. Global Biosimilar Insulin Production Capacity (2017-2028) & (K Unit)
Figure 15. Global Biosimilar Insulin Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. Biosimilar Insulin Market Drivers
Figure 17. Biosimilar Insulin Market Restraints
Figure 18. Biosimilar Insulin Market Trends
Figure 19. Global Biosimilar Insulin Sales Market Share by Manufacturer in 2021
Figure 20. Global Biosimilar Insulin Revenue Market Share by Manufacturer in 2021
Figure 21. Biosimilar Insulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 Biosimilar Insulin Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 Biosimilar Insulin Manufacturer (Revenue) Market Share in 2021
Figure 24. Global Biosimilar Insulin Sales Market Share by Region (2017-2028)
Figure 25. Global Biosimilar Insulin Revenue Market Share by Region (2017-2028)
Figure 26. North America Biosimilar Insulin Revenue (2017-2028) & (USD Million)
Figure 27. Europe Biosimilar Insulin Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific Biosimilar Insulin Revenue (2017-2028) & (USD Million)
Figure 29. South America Biosimilar Insulin Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa Biosimilar Insulin Revenue (2017-2028) & (USD Million)
Figure 31. Global Biosimilar Insulin Sales Market Share by Type (2017-2028)
Figure 32. Global Biosimilar Insulin Revenue Market Share by Type (2017-2028)
Figure 33. Global Biosimilar Insulin Price by Type (2017-2028) & (US$/Unit)
Figure 34. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2017-2028)
Figure 35. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2017-2028)
Figure 36. Global Biosimilar Insulin Price by Distribution Channel (2017-2028) & (US$/Unit)
Figure 37. North America Biosimilar Insulin Sales Market Share by Type (2017-2028)
Figure 38. North America Biosimilar Insulin Sales Market Share by Distribution Channel (2017-2028)
Figure 39. North America Biosimilar Insulin Sales Market Share by Country (2017-2028)
Figure 40. North America Biosimilar Insulin Revenue Market Share by Country (2017-2028)
Figure 41. United States Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Biosimilar Insulin Sales Market Share by Type (2017-2028)
Figure 45. Europe Biosimilar Insulin Sales Market Share by Distribution Channel (2017-2028)
Figure 46. Europe Biosimilar Insulin Sales Market Share by Country (2017-2028)
Figure 47. Europe Biosimilar Insulin Revenue Market Share by Country (2017-2028)
Figure 48. Germany Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Biosimilar Insulin Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Biosimilar Insulin Sales Market Share by Distribution Channel (2017-2028)
Figure 55. Asia-Pacific Biosimilar Insulin Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Biosimilar Insulin Revenue Market Share by Region (2017-2028)
Figure 57. China Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America Biosimilar Insulin Sales Market Share by Type (2017-2028)
Figure 64. South America Biosimilar Insulin Sales Market Share by Distribution Channel (2017-2028)
Figure 65. South America Biosimilar Insulin Sales Market Share by Country (2017-2028)
Figure 66. South America Biosimilar Insulin Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa Biosimilar Insulin Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa Biosimilar Insulin Sales Market Share by Distribution Channel (2017-2028)
Figure 71. Middle East & Africa Biosimilar Insulin Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa Biosimilar Insulin Revenue Market Share by Region (2017-2028)
Figure 73. Turkey Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa Biosimilar Insulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of Biosimilar Insulin in 2021
Figure 78. Manufacturing Process Analysis of Biosimilar Insulin
Figure 79. Biosimilar Insulin Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
